Do you continue somatostatin analogs beyond progression to maintain disease control in low-intermediate grade neuroendocrine tumors?
If so, are there particular patient/tumor characteristics that influence your decision?
Community PollStarted
Do you continue somatostatin analogues beyond progression in well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
50 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on
Unfortunately there is no clear data on whether to continue somatostatin analogues (SSA) upon progression in NETs. Certainly for a functional tumor (ie carcinoid syndrome) it makes perfect sense to continue an SSA.
An exception to continuing SSA upon progression is considered when we examine the NETT...
Join for free or sign in to see the full answer